Asgard Therapeutics posted on X:
“Asgard Therapeutics’s new paper in Science showing how our lead product AT-108 directly reprograms tumor cells within the TME to become functional antigen-presenting dendritic cells, triggering strong anti-tumour responses.
More.”
Source: Asgard Therapeutics/X